EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 176 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 October is National Dental Hygiene Month October 1, 2020 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 UK health inequalities: 20,000 more cancer cases a year in the... September 29, 2020 Load more HOT NEWS What to Say to Someone With Cancer: A Patient Perspective Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma ESMO Virtual Congress 2020, 19-21 September [ESMO Media Alert]
